mRNA |
BRD1812 |
CTRPv2 |
pan-cancer |
AAC |
-0.14 |
0.0001 |
mRNA |
Nilotinib |
GDSC1000 |
pan-cancer |
AAC |
-0.14 |
0.0001 |
mRNA |
navitoclax:piperlongumine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.12 |
0.0005 |
mRNA |
Nilotinib |
CCLE |
pan-cancer |
AAC |
-0.17 |
0.0006 |
mRNA |
GNF-2 |
GDSC1000 |
pan-cancer |
AAC |
-0.17 |
0.0007 |
mRNA |
decitabine:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.1 |
0.0008 |
mRNA |
ABT-263 |
CTRPv2 |
pan-cancer |
AAC |
-0.12 |
0.001 |
mRNA |
BRD-K28456706 |
CTRPv2 |
pan-cancer |
AAC |
-0.12 |
0.001 |
mRNA |
selumetinib:navitoclax (8:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.11 |
0.002 |
mRNA |
Methotrexate |
CTRPv2 |
pan-cancer |
AAC |
0.11 |
0.002 |